Other drug discovery initiatives are trying to develop effective inhibitors of tryptophan hydroxylase 1 (TPH1, the isoform expressed in GIT), which are unable to pass the blood-brain barrier, as an alternative to reduce 5-HT synthesis by EC cells, and consequently reduce/avoid their deleterious effects induced by dysregulation of the gastrointestinal serotonergic system (for instance IBS and carcinoid syndrome) [180,181]. This evidence concerns the gene TPH1 and carcinoid syndrome.